The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction

Eur Heart J. 2012 Feb;33(3):384-92. doi: 10.1093/eurheartj/ehr301. Epub 2011 Aug 19.

Abstract

Aims: ST-elevation in lead aVR is known to be associated with a worse prognosis in patients with acute ST elevation myocardial infarction (MI) but the significance of ST depression in lead aVR has been unclear. Infarction of the inferior apex of the left ventricle may not be appreciated on the standard 12-lead electrocardiogram (ECG) except by observing ST depression in lead aVR which is reciprocal to lead V(7). We therefore determined the prognostic value of the full spectrum of aVR ST changes in patients presenting with acute ST elevation MI.

Methods and results: Lead aVR ST level was measured on randomization and 60 min ECGs in 15 315 patients with normal conduction from the HERO-2 trial. The outcome measure was 30-day mortality. aVR ST elevation ≥1 mm was associated with higher 30-day mortality for both inferior (22.5% for ≥1.5 mm and 13.2% for 1 mm) and anterior (23.5% for ≥1.5 mm and 11.5% for 1 mm) infarction. In contrast, deeper aVR ST depression (0, 0.5, 1, and ≥1.5 mm) was associated with higher mortality for anterior infarction (9.8, 13.2, 12.8, and 16.8%, respectively, trend P-value <0.0001) but not for inferior infarction. The resolution of aVR ST depression and ST elevation 60 min after fibrinolysis was associated with lower mortality.

Conclusion: There is a U-shaped relationship between 30-day mortality and aVR ST level in patients presenting with anterior but not inferior ST elevation MI.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antithrombins / therapeutic use
  • Aspirin / therapeutic use
  • Electrocardiography / methods*
  • Electrocardiography / mortality
  • Female
  • Fibrinolytic Agents
  • Heparin / therapeutic use
  • Hirudins
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / mortality*
  • Peptide Fragments / therapeutic use
  • Prognosis
  • Recombinant Proteins / therapeutic use
  • Streptokinase / therapeutic use

Substances

  • Antithrombins
  • Fibrinolytic Agents
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Heparin
  • Streptokinase
  • Aspirin
  • bivalirudin